Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Buy
56
BMRN Quote, Financials, Valuation and Earnings
Last price:
$61.97
Seasonality move
:
6.39%
Day range:
$60.92 - $65.40
52-week range:
$52.93 - $94.85
Dividend yield:
0%
P/E ratio:
23.06x
P/S ratio:
4.16x
P/B ratio:
2.05x
Volume:
2.2M
Avg. volume:
1.9M
1-year change:
-25.98%
Market cap:
$11.9B
Revenue:
$2.9B
EPS (TTM):
$2.69
Analysts' Opinion
-
Consensus RatingBiomarin Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $96.02, Biomarin Pharmaceutical has an estimated upside of 54.79% from its current price of $62.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing -4.79% downside risk from its current price of $62.03.
Fair Value
-
According to the consensus of 22 analysts, Biomarin Pharmaceutical has 54.79% upside to fair value with a price target of $96.02 per share.
BMRN vs. S&P 500
-
Over the past 5 trading days, Biomarin Pharmaceutical has underperformed the S&P 500 by -4.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biomarin Pharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomarin Pharmaceutical has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Biomarin Pharmaceutical reported revenues of $745.1M.
Earnings Growth
-
Biomarin Pharmaceutical has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Biomarin Pharmaceutical reported earnings per share of $0.95.
Enterprise value:
11.2B
EV / Invested capital:
1.76x
Price / LTM sales:
4.16x
EV / EBIT:
16.36x
EV / Revenue:
3.80x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
18.09x
Price / Operating cash flow:
19.78x
Enterprise value / EBITDA:
14.44x
Gross Profit (TTM):
$2.3B
Return On Assets:
7.5%
Net Income Margin (TTM):
17.76%
Return On Equity:
9.62%
Return On Invested Capital:
8.4%
Operating Margin:
30.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.5B | $3B | $648.8M | $745.1M | |
| Gross Profit | $1.7B | $1.9B | $2.3B | $523.7M | $593.6M | |
| Operating Income | $88.5M | $245M | $619.6M | $78.5M | $223.9M | |
| EBITDA | $186.9M | $356.3M | $777.1M | $136.4M | $263M | |
| Diluted EPS | $0.38 | $1.07 | $2.69 | $0.46 | $0.95 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.4B | $2.8B | $3B | $3.5B | |
| Total Assets | $5.8B | $6.1B | $6.4B | $6.9B | $7.1B | |
| Current Liabilities | $430M | $490.4M | $598.2M | $1.1B | $628.2M | |
| Total Liabilities | $1.6B | $1.7B | $1.8B | $1.8B | $1.4B | |
| Total Equity | $4.2B | $4.4B | $4.7B | $5.1B | $5.8B | |
| Total Debt | $1.1B | $1.1B | $1.1B | $1.1B | $595.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $147.4M | $280.2M | $700.3M | $47M | $174.4M | |
| Cash From Investing | -$137.8M | -$95.5M | $122.5M | -$14.2M | -$28.2M | |
| Cash From Financing | -$34.1M | -$20.8M | -$522.4M | -$42.8M | -$38.8M | |
| Free Cash Flow | $21.8M | $163.2M | $620.2M | $12.9M | $157.6M | |
BMRN
Sector
Market Cap
$11.9B
$35.8M
Price % of 52-Week High
65.4%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-25.98%
-38.89%
Beta (5-Year)
0.268
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$62.83
200-day SMA
Sell
Level
$71.08
Bollinger Bands (100)
Sell
Level
61.63 - 69.67
Chaikin Money Flow
Buy
Level
172.3M
20-day SMA
Buy
Level
$60.42
Relative Strength Index (RSI14)
Sell
Level
46.03
ADX Line
Sell
Level
23.84
Williams %R
Neutral
Level
-42.0724
50-day SMA
Sell
Level
$66.39
MACD (12, 26)
Sell
Level
-0.81
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
248.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.7343)
Buy
CA Score
(Annual)
Level (1.2841)
Buy
Beneish M-Score
(Annual)
Level (-2.424)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-3.8579)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Stock Forecast FAQ
In the current month, BMRN has received 16 Buy ratings 6 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $96.02.
-
Where Will Biomarin Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomarin Pharmaceutical share price will rise to $96.02 per share over the next 12 months.
-
What Do Analysts Say About Biomarin Pharmaceutical?
Analysts are divided on their view about Biomarin Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomarin Pharmaceutical is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Biomarin Pharmaceutical's Price Target?
The price target for Biomarin Pharmaceutical over the next 1-year time period is forecast to be $96.02 according to 22 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is BMRN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomarin Pharmaceutical is a Buy. 16 of 22 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BMRN?
You can purchase shares of Biomarin Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomarin Pharmaceutical shares.
-
What Is The Biomarin Pharmaceutical Share Price Today?
Biomarin Pharmaceutical was last trading at $61.97 per share. This represents the most recent stock quote for Biomarin Pharmaceutical. Yesterday, Biomarin Pharmaceutical closed at $62.03 per share.
-
How To Buy Biomarin Pharmaceutical Stock Online?
In order to purchase Biomarin Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
